DK3223822T3 - Gilsyrederivater som fxr / tgr5 agonister - Google Patents

Gilsyrederivater som fxr / tgr5 agonister Download PDF

Info

Publication number
DK3223822T3
DK3223822T3 DK15864209.0T DK15864209T DK3223822T3 DK 3223822 T3 DK3223822 T3 DK 3223822T3 DK 15864209 T DK15864209 T DK 15864209T DK 3223822 T3 DK3223822 T3 DK 3223822T3
Authority
DK
Denmark
Prior art keywords
fxr
acid derivatives
tgr5 agonists
gilic
gilic acid
Prior art date
Application number
DK15864209.0T
Other languages
English (en)
Inventor
Guoqiang Wang
Yat Sun Or
Ruichao Shen
Jiang Long
Peng Dai
Xuechao Xing
Jing He
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Application granted granted Critical
Publication of DK3223822T3 publication Critical patent/DK3223822T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK15864209.0T 2014-11-26 2015-11-27 Gilsyrederivater som fxr / tgr5 agonister DK3223822T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462084769P 2014-11-26 2014-11-26
US201562103374P 2015-01-14 2015-01-14
US14/951,989 US10208081B2 (en) 2014-11-26 2015-11-25 Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
PCT/US2015/062826 WO2016086218A1 (en) 2014-11-26 2015-11-27 Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof

Publications (1)

Publication Number Publication Date
DK3223822T3 true DK3223822T3 (da) 2020-09-07

Family

ID=56075071

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15864209.0T DK3223822T3 (da) 2014-11-26 2015-11-27 Gilsyrederivater som fxr / tgr5 agonister

Country Status (26)

Country Link
US (5) US10208081B2 (da)
EP (1) EP3223822B1 (da)
JP (1) JP6857124B2 (da)
KR (1) KR102543268B1 (da)
CN (1) CN107106575B (da)
AU (1) AU2015353372B2 (da)
CA (1) CA2968673C (da)
CY (1) CY1123595T1 (da)
DK (1) DK3223822T3 (da)
ES (1) ES2815624T3 (da)
HK (1) HK1244707A1 (da)
HR (1) HRP20201420T1 (da)
HU (1) HUE051971T2 (da)
IL (2) IL252449A0 (da)
LT (1) LT3223822T (da)
MX (1) MX2017006832A (da)
NZ (1) NZ732154A (da)
PH (1) PH12017500941A1 (da)
PL (1) PL3223822T3 (da)
PT (1) PT3223822T (da)
RS (1) RS60836B1 (da)
RU (1) RU2707280C2 (da)
SG (2) SG10201909545XA (da)
SI (1) SI3223822T1 (da)
WO (1) WO2016086218A1 (da)
ZA (2) ZA201704154B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
RU2017118569A (ru) 2014-11-06 2018-12-06 Энанта Фармасьютикалс, Инк. Аналоги желчных кислот как агонисты fxr/tgr5 и способы их применения
TWI686401B (zh) 2014-11-19 2020-03-01 英商Ｎｚｐ英國有限公司 化合物（三）
DK3221332T3 (da) 2014-11-19 2019-07-29 Nzp Uk Ltd Fremstilling af steroide fxr-modulatorer
CA2968309A1 (en) 2014-11-19 2016-05-26 NZP UK Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
MX2017006567A (es) 2014-11-19 2018-01-26 Nzp Uk Ltd Esteroides 6.alfa.-alquil-6,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
BR112017010893A2 (pt) 2014-11-26 2018-02-06 Enanta Pharm Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
RS62110B1 (sr) 2015-03-31 2021-08-31 Enanta Pharm Inc Derivati žučnih kiselina kao agonisti fxr/tgr5 i postupci njihove upotrebe
ES2873088T3 (es) 2015-06-19 2021-11-03 Intercept Pharmaceuticals Inc Moduladores de TGR5 y métodos para su uso
TW201700447A (zh) * 2015-06-19 2017-01-01 英特賽普醫藥品公司 Tgr5調控劑及其用法
EP3409684B1 (en) * 2016-01-28 2024-01-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Steroid derivative fxr agonist
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
EA038580B9 (ru) * 2016-05-18 2021-10-05 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Агонист fxr, представляющий собой производное стероидов
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CA3026512A1 (en) 2016-06-13 2017-12-21 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CN108017636A (zh) 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
AU2017368069B2 (en) * 2016-11-29 2021-07-08 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
WO2018153933A1 (en) 2017-02-21 2018-08-30 Genfit Combination of a ppar agonist with a fxr agonist
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
BR112019020780A2 (pt) * 2017-04-07 2020-04-28 Enanta Pharm Inc processo para preparação de derivados de ácido biliar de carbamato de sulfonila
BR112019027458A2 (pt) 2017-06-23 2020-07-07 Intercept Pharmaceuticals, Inc. métodos e intermediários para a preparação de derivados de ácidos biliares
KR20200041337A (ko) 2017-08-15 2020-04-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
JP6948680B2 (ja) * 2017-12-19 2021-10-13 西安奥立泰医薬科技有限公司Ｘｉ’Ａｎ Ｂｉｏｃａｒｅ Ｐｈａｒｍａ Ｌｔｄ． 代謝性疾患治療用化合物及びその製造方法、並びに応用
JP7073533B2 (ja) * 2018-05-01 2022-05-23 メルク・シャープ・アンド・ドーム・コーポレーション スピロピペリジン系ニコチン性アセチルコリン受容体アロステリック調節剤
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
EP4360632A3 (en) 2019-01-15 2024-06-19 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
EP3927683A1 (en) 2019-02-19 2021-12-29 Gilead Sciences, Inc. Solid forms of fxr agonists
WO2023288123A1 (en) 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
WO2023083343A1 (en) * 2021-11-15 2023-05-19 Hepaitech (Beijing) Biopharma Technology Co., Ltd. Polycyclic compounds and methods thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1592791A (en) 1977-01-07 1981-07-08 Radiochemical Centre Ltd Selenium- or tellurium-containing bile acids and derivatives thereof
WO1987002367A2 (en) 1985-10-18 1987-04-23 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
IT1255449B (it) 1992-06-30 1995-10-31 Fabio Berlati Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
IT1255485B (it) 1992-08-04 1995-11-06 Erregierre Ind Chim Processo per preparare gli acidi biliari coniugati con la glicina e relative composizioni terapeutiche per il trattamento dell'insufficienza epatica
TW289757B (da) 1993-05-08 1996-11-01 Hoechst Ag
TW289020B (da) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
US5541348A (en) 1994-03-10 1996-07-30 National Research Council Of Canada Bile acids for biological and chemical applications and processes for the production thereof
WO1995026325A2 (en) 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US5646316A (en) 1994-04-08 1997-07-08 Osteoarthritis Sciences, Inc. Bile acid inhibitors of metalloproteinase enzymes
JPH1160594A (ja) 1997-08-25 1999-03-02 Sankyo Co Ltd 胆汁酸誘導体
JP3865890B2 (ja) 1997-09-30 2007-01-10 富士フイルムホールディングス株式会社 ポジ型感光性組成物
AU2389100A (en) 1998-12-23 2000-07-12 Glaxo Group Limited Assays for ligands for nuclear receptors
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
DE60139875D1 (de) 2000-07-26 2009-10-22 Us Gov Health & Human Serv 5-substituierte pyrimidinderivate eines konformatiosfestgelegten nukleosidanalogen
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US20020098999A1 (en) 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
ES2248581T3 (es) 2001-03-12 2006-03-16 Intercept Pharmaceuticals, Inc. Esteroides como agonistas de fxr.
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
ITMI20021080A1 (it) 2002-05-21 2003-11-21 Marcello Izzo Associazioni farmaceutiche per uso topico a base di chelati del ferroinibitori delle metalloproteasi e fattore xiii per il trattamento dell
EP1562915A1 (en) 2002-11-22 2005-08-17 SmithKline Beecham Corporation Farnesoid x receptor agonists
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
US9498484B2 (en) 2004-03-12 2016-11-22 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
WO2006113204A2 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thymidine derivatives for treatmemt of kaposi's sarcoma
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US7705028B2 (en) 2005-12-19 2010-04-27 Glaxosmithkline Llc Farnesoid X receptor agonists
WO2007089907A2 (en) * 2006-02-01 2007-08-09 Brigham Young University Cationic steroid antimicrobial compositions and methods of use
WO2007092751A2 (en) 2006-02-03 2007-08-16 Eli Lilly And Company Compounds and methods for modulating fx-receptors
WO2007095174A2 (en) 2006-02-14 2007-08-23 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
US20090131384A1 (en) 2006-03-22 2009-05-21 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
WO2007140183A1 (en) 2006-05-24 2007-12-06 Eli Lilly And Company Fxr agonists
PE20080259A1 (es) 2006-05-24 2008-04-10 Lilly Co Eli Compuestos y metodos para modular fxr
WO2008002573A2 (en) 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
RU2009105179A (ru) 2006-07-17 2010-08-27 Новартис АГ (CH) Сульфониламинокарбонилпроизводные амидов холевой кислоты для применения в качестве иммуномодуляторов
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
WO2008091540A2 (en) 2007-01-19 2008-07-31 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as tgr5 modulators and methods of use thereof
EP1947108A1 (en) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
WO2008101665A1 (en) 2007-02-20 2008-08-28 Novartis Ag Macrocyclic compounds as hcv ns3 protease inhibitors
CN101977505A (zh) 2007-06-13 2011-02-16 葛兰素史密丝克莱恩有限责任公司 类法尼醇x受体激动剂
AU2008270784A1 (en) 2007-07-02 2009-01-08 Glaxosmithkline Llc Farnesoid X receptor agonists
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
EP2188299B1 (en) 2007-09-06 2017-10-25 Ohr Pharmaceutical, Inc. Compounds for treating diabetes
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
KR101239008B1 (ko) 2008-03-31 2013-03-04 한양대학교 산학협력단 바일산 유도체 및 그의 응용
US8796249B2 (en) 2008-07-30 2014-08-05 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
WO2010030858A1 (en) 2008-09-15 2010-03-18 Enanta Pharmaceuticals, Inc. 4'-allene-substituted nucleoside derivatives
US8603737B2 (en) 2008-09-19 2013-12-10 Celgene Avilomics Research, Inc. Methods for identifying HCV protease inhibitors
WO2010093845A1 (en) * 2009-02-12 2010-08-19 Exelixis, Inc. Triazole and imidazole derivatives for use as tgr5 agonists in the treatment of diabetes and obesity
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013020108A2 (en) 2011-08-04 2013-02-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pancreatitis
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
KR20150004894A (ko) 2012-05-01 2015-01-13 카타베이시스 파마슈티칼즈, 인코포레이티드 스타틴 및 ｆｘｒ 작용제의 지방산 컨쥬게이트들； 조성물 및 이용 방법
EA032347B1 (ru) 2012-06-19 2019-05-31 Интерсепт Фармасьютикалз, Инк. Получение, применение и твердые формы обетихолевой кислоты
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
WO2014036377A1 (en) 2012-08-31 2014-03-06 Metselex Methods of promoting cell viability
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140206657A1 (en) 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
JP6326131B2 (ja) 2013-05-14 2018-05-16 インターセプト ファーマシューティカルズ， インコーポレイテッド ファルネソイドｘ受容体調節物質としての、胆汁酸の１１−ヒドロキシル誘導体およびそのアミノ酸抱合体
CN105593237B (zh) 2013-08-01 2019-06-04 美国卫生和人力服务部 法尼醇x受体的抑制剂和在医学中的用途
US20150112089A1 (en) 2013-10-22 2015-04-23 Metselex, Inc. Deuterated bile acids
MX2020004024A (es) 2014-05-29 2021-12-10 Bar Pharmaceuticals S R L Derivados del colano para uso en el tratamiento y/o prevencion de enfermedades en las que intervienen el fxr y el tgr5/gpbar1.
RU2017118569A (ru) 2014-11-06 2018-12-06 Энанта Фармасьютикалс, Инк. Аналоги желчных кислот как агонисты fxr/tgr5 и способы их применения
CN105669811B (zh) 2014-11-17 2020-09-04 正大天晴药业集团股份有限公司 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途
WO2016086134A1 (en) * 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US20160176917A1 (en) 2014-11-26 2016-06-23 Enanta Pharmaceuticals, Inc. Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof
BR112017010893A2 (pt) 2014-11-26 2018-02-06 Enanta Pharm Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
BR112017017238A2 (pt) 2015-02-11 2018-04-10 Enanta Pharm Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
RS62110B1 (sr) 2015-03-31 2021-08-31 Enanta Pharm Inc Derivati žučnih kiselina kao agonisti fxr/tgr5 i postupci njihove upotrebe
US20180148470A1 (en) 2015-04-28 2018-05-31 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Cholic acid derivative, and preparation method and medical use thereof
CN106083978A (zh) 2015-04-28 2016-11-09 上海迪诺医药科技有限公司 磺酰基氨基羰基衍生物、其药物组合物及应用
WO2016173524A1 (zh) 2015-04-29 2016-11-03 正大天晴药业集团股份有限公司 鹅去氧胆酸衍生物
TW201700447A (zh) 2015-06-19 2017-01-01 英特賽普醫藥品公司 Tgr5調控劑及其用法
BR112018002499A2 (pt) 2015-08-07 2018-09-18 Intercept Pharmaceuticals Inc método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
CN105175473B (zh) 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用
CN108350020A (zh) 2015-09-24 2018-07-31 英特塞普特医药品公司 用于制备胆汁酸衍生物的方法和中间体
TW201718621A (zh) 2015-10-07 2017-06-01 英特賽普醫藥品公司 法尼醇x受體調節劑
EP3409684B1 (en) 2016-01-28 2024-01-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Steroid derivative fxr agonist
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
AU2017229481B2 (en) 2016-03-11 2022-06-16 Intercept Pharmaceuticals, Inc. 3-desoxy derivative and pharmaceutical compositions thereof
US11780885B2 (en) 2016-11-17 2023-10-10 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
AU2017368069B2 (en) 2016-11-29 2021-07-08 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
BR112019020780A2 (pt) 2017-04-07 2020-04-28 Enanta Pharm Inc processo para preparação de derivados de ácido biliar de carbamato de sulfonila

Also Published As

Publication number Publication date
CY1123595T1 (el) 2022-03-24
SG10201909545XA (en) 2019-11-28
HRP20201420T1 (hr) 2020-12-11
US20160185815A1 (en) 2016-06-30
RU2707280C2 (ru) 2019-11-26
EP3223822A4 (en) 2018-07-11
JP6857124B2 (ja) 2021-04-14
ZA201908293B (en) 2021-04-28
IL252449A0 (en) 2017-07-31
AU2015353372B2 (en) 2020-07-23
WO2016086218A1 (en) 2016-06-02
JP2017536379A (ja) 2017-12-07
EP3223822A1 (en) 2017-10-04
EP3223822B1 (en) 2020-07-01
CA2968673C (en) 2023-07-11
NZ732154A (en) 2022-10-28
SI3223822T1 (sl) 2020-11-30
US20240140984A1 (en) 2024-05-02
KR20170087935A (ko) 2017-07-31
PL3223822T3 (pl) 2021-01-11
RU2017120970A3 (da) 2018-12-26
BR112017011126A2 (pt) 2018-01-23
US20210261600A1 (en) 2021-08-26
US11718641B2 (en) 2023-08-08
KR102543268B1 (ko) 2023-06-13
CN107106575A (zh) 2017-08-29
PT3223822T (pt) 2020-08-31
ZA201704154B (en) 2020-03-25
RS60836B1 (sr) 2020-10-30
HK1244707A1 (zh) 2018-08-17
LT3223822T (lt) 2020-10-12
AU2015353372A1 (en) 2017-06-15
US10696713B2 (en) 2020-06-30
HUE051971T2 (hu) 2021-04-28
CA2968673A1 (en) 2016-06-02
US10208081B2 (en) 2019-02-19
RU2017120970A (ru) 2018-12-26
CN107106575B (zh) 2021-04-13
IL273567A (en) 2020-05-31
US20200347092A1 (en) 2020-11-05
MX2017006832A (es) 2018-02-13
US10968249B2 (en) 2021-04-06
PH12017500941A1 (en) 2017-11-20
ES2815624T3 (es) 2021-03-30
US20190194245A1 (en) 2019-06-27
SG11201704227QA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
DK3223822T3 (da) Gilsyrederivater som fxr / tgr5 agonister
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3190113T3 (da) Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
DK3556777T3 (da) Multispecifikke antistofkonstrukter
DK3220988T3 (da) Intranasal administration
DK3204381T3 (da) N-pyridinylacetamidderivater som wnt-signaleringsbanehæmmere
DK3094631T3 (da) Pyrimidinyloxybenzenderivater som herbicider
DK3286177T3 (da) Quinolinderivater som tam rtk-inhibitorer
DK3201206T3 (da) Borsyrederivater
DK3143047T3 (da) Belimumab-formulering
DK3194411T3 (da) Nukleotidanaloger
DK3204378T3 (da) N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3231803T3 (da) Dihydroindolizinonderivat
IL246345A0 (en) History of 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid as neprilysin inhibitors
DK3131898T3 (da) Fluoroalkylfluorenderivativer
DK3792251T3 (da) Hidtil ukendte sulfonylaminobenzamidforbindelser som anthelmintika
DK3097076T3 (da) Hidtil ukendte cyp-eicosanoidderivater
DE112015003475A5 (de) Spannfutter
DK3319970T3 (da) Pyrido-oxazinonderivater som tnap-hæmmere
DK2913321T3 (da) Hidtil ukendte cannabigerolderivater
DK3233839T3 (da) Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer
DK3148513T3 (da) Ceritinib-formulering
DK3199160T3 (da) Vandig sammensætning